HIV RNA检测监测口服暴露前预防用药的实用性有限:2019-2023年美国真实世界队列研究
本研究利用HealthVerity数据库构建口服PrEP使用者队列,比较2019-2021年与2022-2023年两个时期HIV RNA检测的使用情况与性能。结果显示,指南更新后随访HIV RNA检测率从每100人年16次增至123次,RNA检测阳性率从1.39%降至0.22%,HIV RNA检测的阳性预测值从100%降至67%。结论认为HIV RNA检测在口服PrEP常规随访中未提供额外价值。
要点
- 指南更新后随访HIV RNA检测率从每100人年16次增至123次,阳性率从1.39%降至0.22%。
- HIV RNA检测在PrEP随访中的阳性预测值从100%降至67%。
- 每检出1例早于Ag/Ab检测的HIV诊断,估计需8226-9900次RNA检测。
核心结论
- HIV RNA检测在口服PrEP使用者常规随访中未提供额外价值。
- 考虑到HIV RNA检测的成本和物流复杂性,其作为口服PrEP使用者随访常规检测的用途值得重新考虑。
研究设计与样本
- 利用HealthVerity数据库构建口服PrEP使用者队列,包含2018年12月至2023年8月的关联诊断、实验室检测和处方数据。
- 数据按指南更新前(2019-2021年)和指南更新后(2022-2023年)两个时期分层。
- 每个时期评估同日HIV Ag/Ab与RNA结果的一致性,并计算HIV Ag/Ab和RNA检测与 adjudicated HIV状态相比的假阳性率和阳性预测值。
主要发现
- 随访HIV RNA检测率从指南更新前的每100人年16次增至更新后的每100人年123次。
- HIV RNA检测阳性率从1.39%降至0.22%。
- Ag/Ab与RNA结果间的总体一致性保持较高。
- HIV Ag/Ab和RNA检测的假阳性率保持相似,但PrEP随访中HIV RNA检测的阳性预测值从100%降至67%。
- 估计需要8226-9900次RNA检测才能检出1例早于单独Ag/Ab检测发现的HIV诊断。
关键数值与推荐
- 2021年美国CDC HIV PrEP临床指南更新推荐在PrEP启动和常规随访时同时进行抗原抗体(Ag/Ab)和RNA检测。
临床怎么用
- HIV RNA检测在口服PrEP使用者常规随访中未提供额外价值。
- 考虑到HIV RNA检测的成本和物流复杂性,其作为口服PrEP使用者随访常规检测的用途值得重新考虑。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2021 update of the Centers for Disease Control and Prevention clinical guidelines for human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) recommended both antigen-antibody (Ag/Ab) and RNA testing at PrEP initiation and routine follow-up. We assessed the real-world use and performance of HIV tests among oral PrEP users. METHODS: An oral PrEP user cohort was constructed using the HealthVerity database that included linked diagnoses, laboratory tests, and prescriptions from December 2018 to August 2023. Data were stratified by pre-guideline update (2019-2021) and post-guideline update (2022-2023) periods. For each period, we assessed the agreement between same-day HIV Ag/Ab and RNA results and calculated the false-positive rates and positive predictive values of HIV Ag/Ab and RNA tests compared with the adjudicated HIV status. RESULTS: The HIV RNA testing rate for follow-up, per 100 person-years, increased from 16 before to 123 after the guideline update. The positivity rate of HIV RNA tests decreased from 1.39% to 0.22%. Overall agreement between Ag/Ab and RNA results remained high. The false-positive rates of HIV Ag/Ab and RNA testing remained similar, but the positive predictive value of HIV RNA testing for PrEP follow-up decreased from 100% to 67%. We estimated that 8226-9900 RNA tests would be needed for 1 HIV diagnosis earlier than would be detected with Ag/Ab testing alone. DISCUSSION: HIV RNA testing did not provide additional value to Ag/Ab testing during routine follow-up of oral PrEP users. Considering the cost and logistical complexity of HIV RNA testing, its use as a routine test during follow-up of oral PrEP users warrants reconsideration.
引用
- Zhu W, Delaney KP, Huang YA, et al. Limited Utility of HIV RNA Testing to Monitor Oral Preexposure Prophylaxis Use: A Real-World Cohort Study-United States, 2019-2023. Clin Infect Dis. 2025. PMID: 40323767. doi:10.1093/cid/ciaf230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。